問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

List

1336Cases

2020-10-31 - 2021-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2022-08-15 - 2024-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-07-01 - 2021-12-23

Phase III

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

  • Condition/Disease

    Primary Breast Cancer

  • Test Drug

    Ibrance

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2021-12-04 - 2023-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2008-12-01 - 2011-11-30

Phase III

A randomised, double-blind, parallel-group placebo-controlled phase Ill study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke

  • Condition/Disease

    Ischemic stroke

  • Test Drug

    Desmoteplase

Participate Sites
6Sites

Terminated6Sites

劉景寬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2011-07-01 - 2015-07-31

Phase III

A Randomized, Double-Blind, Parallel, Vehicle-Controlled Phase III Trail to Assess the Efficacy and Safety of Topical SR-T100 Gel in the Treatment of Patients with Actinic Keratosis

  • Condition/Disease

    Actinic Keratosis

  • Test Drug

    SR-T100

Participate Sites
6Sites

Terminated6Sites

王德華
National Taiwan University Hospital

Division of Dermatology

2017-03-01 - 2019-12-31

Phase III

A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

  • Condition/Disease

    Advanced or Metastatic Gastric Cancer

  • Test Drug

    Apatinib

Participate Sites
10Sites

Terminated8Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2021-11-19 - 2023-05-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-04-01 - 2022-05-31

Phase III

A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

  • Condition/Disease

    idiopathic pulmonary fibrosis

  • Test Drug

    GLPG1690 (G451990)

Participate Sites
5Sites

Recruiting4Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2019-08-31 - 2024-06-03

Phase III

A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping

  • Condition/Disease

    Duchenne Muscular Dystrophy

  • Test Drug

    Eteplirsen

Participate Sites
2Sites

Recruiting2Sites

1 89 90 91 92 93 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB